Overview

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
Phase:
Phase 4
Details
Lead Sponsor:
Eisai Inc.
Pfizer
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin